Acylcarnitine Abnormalities Implicate Mitochondrial Dysfunction in Patients With Neovascular Age-Related Macular...

Area of Science:

• Ophthalmology
• Metabolomics
• Biochemistry

Background:

• Lipid metabolism abnormalities are linked to age-related macular degeneration (AMD).
• Specific metabolic pathways contributing to AMD pathogenesis remain largely unknown.
• Acylcarnitines serve as crucial markers for lipid and mitochondrial metabolism.

Purpose of the Study:

• To investigate differences in acylcarnitine concentrations between patients with neovascular AMD and control subjects.
• To explore the role of lipid and mitochondrial metabolism in AMD.
• To identify potential metabolic biomarkers for AMD.

Main Methods:

• A cross-sectional case-control study involving 81 neovascular AMD patients and 79 controls.
• Plasma samples analyzed using liquid chromatography-mass spectrometry for acylcarnitine profiling.
• Statistical adjustments for age, gender, and smoking, with confirmation via high-resolution mass spectrometry.

Main Results:

• Significantly lower plasma levels of C2-carnitine (acetylcarnitine) were found in neovascular AMD patients compared to controls (p = 0.002).
• Significantly higher plasma levels of C18:2-DC carnitine were observed in neovascular AMD patients versus controls (p = 0.001).
• No significant differences in other examined acylcarnitines between the groups.

Conclusions:

• Neovascular AMD is associated with reduced acetylcarnitine and increased C18:2-DC carnitine plasma levels.
• These metabolic alterations suggest a potential role for mitochondrial dysfunction in the development of neovascular AMD.
• Acylcarnitine profiling may offer insights into AMD pathophysiology.